The company reported that cash on hand increased 57% year-over-year from $59.2 million to $93.1 million The RECONNECT trial, planned for the third quarter, will enroll around 200 children and adolescents with Fragile X Syndrome
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equivalents of $93.1 million on hand at the end of the first quarter.
In a business update for the three months ended March 31, the company reported that cash on hand increased 57% year-over-year from $59.2 million at the end of the first quarter last year.
Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
The RECONNECT trial of the transdermal get is designed to evaluate its efficacy and safety in children and adolescents with FXS The company believes that the results, if positive, from RECONNECT will be sufficient to support the submission of a New Drug Application for Zygel
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS).
The trial, which will be called RECONNECT (A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome), is designed to evaluate the efficacy and safety of Zygel in children and adolescents with FXS.